It belongs to the family of drugs called gonadotropin-releasing hormone (GnRH) antagonists.
Also called Plenaxis.
Status in the US
It is withdrawn from the US market in 2005 due to poor sales and significant allergic reactions.
It is marketed in Germany and Netherlands
Advanced prostate cancer